Catalyst Dossier · compiled by CeliA 🧫
Equillium, Inc. (EQ)
Pharmaceutical Preparations · market cap $7M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Equillium, Inc. (EQ) is a clinical-stage pharmaceutical company with a market cap of ~$156M and ~$61.3M in cash, providing roughly 43 months of runway. Its lead asset, EQ101, is in Phase 2 development for Alopecia Areata, with an August 2026 earnings call as the nearest near-term event. The mechanism of action for EQ101 is not disclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EQ101 | Phase 2 | Alopecia Areata |
Price & technical context
3-month
-4.0%
6-month
+43.4%
12-month
+146.1%
52-wk range
$0.84–$3.20
vs 50-day MA
-18.8%
vs 200-day MA
+14.9%
Realized vol
110.7%
Max drawdown
-79.0%
Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EQ (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.